Novartis Snaps Up Cardio-Focused Tourmaline Bio For $1.4 Billion

Novartis is acquiring Tourmaline Bio for $1.4 billion, a strategic move following Tourmaline's recent announcement of promising Phase 2 results for its cardiovascular drug, pacibekitug. The drug demonstrated significant reductions in high-sensitivity C-reactive protein (hs-CRP), including a median 85% reduction after 90 days, and offers a potential quarterly dosing advantage over competitors like Novo Nordisk's ziltivekimab. This acquisition provides Novartis with a key cardiometabolic asset, while Tourmaline Bio's shares surged 58% on the news.

Analysis

Novartis (NVS) has agreed to acquire Tourmaline Bio (TRML) for $1.4 billion, a strategic move driven by promising clinical data for Tourmaline's atherosclerotic cardiovascular disease drug, pacibekitug. The acquisition follows Tourmaline's recent announcement that quarterly doses of the drug led to a median 85% reduction in high-sensitivity C-reactive protein (hs-CRP) after 90 days, a key inflammatory biomarker. This performance is notable as it positions pacibekitug competitively against Novo Nordisk's (NVO) ziltivekimab, which requires monthly injections, suggesting a significant dosing advantage. An analyst from Wedbush affirmed the deal's timing as logical, given the strong data and Tourmaline's plans for Phase 3 testing, and views Novartis as an ideal partner with the necessary cardiometabolic expertise. The market reacted decisively, with TRML shares surging 58% to 47.68 in premarket trading, while NVS shares experienced a fractional decline to 128.30, a common reaction for an acquiring company.

Key Decisions for Investors

• For current Tourmaline Bio (TRML) shareholders, the 58% stock surge to 47.68 largely reflects the acquisition premium, indicating that future upside is now capped by the terms of the deal with Novartis.
• Novartis (NVS) investors should interpret this acquisition as a long-term strategic investment to secure a competitive, late-stage asset in the high-value cardiometabolic space, justifying the capital outlay despite the minor short-term stock pressure.
• Investors in the broader cardiovascular biotech sector should note that this $1.4 billion deal sets a valuation benchmark for assets targeting hs-CRP and signals heightened M&A activity, potentially impacting competitors like Novo Nordisk.